PacBio CEO's Words Haunt Patent Invalidity Arguments

By Andrew Karpan · March 25, 2024, 9:24 PM EDT

A California federal judge concluded Monday that statements made by the chief executive officer of biotech company Pacific Biosciences to investors at an earnings call undermined the company's invalidity arguments in...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Take2 Technologies Limited et al v. Pacific Biosciences of California, Inc.

Case Number

Court

California Northern

Nature of Suit

Patent

Date Filed

August 16, 2023

Recent Articles By Andrew

May 14, 2024
The PREP Immunity Question Won't Be Decided Yet
May 13, 2024
USPTO Eyes Change To Patent Applicants' Disclaimer Practice
May 08, 2024
GOP Reps. Want IP Enforcers To Get Tougher On Infringers
April 15, 2024
Hold This COVID Vax Patent Case, Judge Recommends
April 12, 2024
Trade Groups Urge Senators To Advance Patent Reform Bills
April 10, 2024
Justices Asked To Ban FCA Suits Relying On Patent Reviews
April 09, 2024
Calif. Addiction Clinic Can't Shake Off Copyright Suit
April 09, 2024
Court OKs Decision Clearing Contractor Of Missed IP Deadline
April 05, 2024
Abbott Settles TM Suit Over Gray Market Diabetes Test Strips
April 03, 2024
Microsoft Notches Fed. Circ. Win In 3D Imaging Patent Fight